Veru, Inc. (VERU) Reports Q4 Loss of $0.05/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
December 12, 2019 6:30 AM EST--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer--
--VERU-111 Has Promising Signs of Progression Free Survival--Â Â Â Â Â Â Â Â Â Â Â Â Â --Advancing VERU-111 into Three Phase 2 Clinical Studies in Additional Cancer Types--Â Â Â Â Â Â --Company to Host Investor Conference Call Today at 8 a.m. ET to Discuss Financial Results and Clinical Study Data--
MIAMI, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:... More
